QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (87) Citing Articles via Google Scholar Google Scholar Articles by Green, P. S. Articles by Simpkins, J. W. Search for Related Content PubMed PubMed Citation Articles by Green, P. S. Articles by Simpkins, J. W.

 Previous Article  |  Next Article 

Volume 17, Number 2, Issue of January 15, 1997 pp. 511-515
Copyright ©1997 Society for Neuroscience

17-Estradiol Exerts Neuroprotective Effects on SK-N-SH Cells

Pattie S. Green, Jean Bishop, and James W. Simpkins

Center for the Neurobiology of Aging and the Department of Pharmacodynamics, University of Florida, Gainesville, Florida 32610

ABSTRACT

INTRODUCTION

MATERIALS AND METHODS

RESULTS

DISCUSSION

FOOTNOTES

REFERENCES

---

ABSTRACT

Estradiol (E2) has been shown to exert organizational, neurotrophic, and neuroprotective effects in the CNS. The present study assessed the specificity of the neuroprotective effects of estradiol for the potent 17-isomer. SK-N-SH cells from a human neuroblastoma cell line, which we have shown to be estrogen-responsive, were cultured at low or high plating density. Then cells were exposed to 17-E2 (0.2 or 2 nM), 17-E2 (0.2 or 2 nM), or cholesterol, testosterone, dihydrotestosterone, progesterone, or corticosterone (all at 2 nM). Cultures were insulted by serum deprivation, which caused a profound loss of cells. At 1 or 2 d of serum deprivation and steroid hormone replacement, the protection afforded cells by the steroid addition was assessed. Serum deprivation killed ~90% of cells cultured at both low and high plating density. Both 17- and 17-E2 provided protection of SK-N-SH cells at either plating density. Further, a 10-fold molar excess of tamoxifen antagonized only approximately one-third of the neuroprotective effects of either isomer of estradiol, and a 100-fold excess of tamoxifen had no additional effect on the neuroprotection by 17-E2. By contrast, none of the other steroids tested protected cells from the insult of serum deprivation. These results indicate that the neuroprotective effects of estrogens are not attributable to the general steroid structure, and the majority of the neuroprotection may not be mediated via a tamoxifen-antagonized receptor mechanism.

Key words: estrogens; 17-estradiol; 17-estradiol; neuroprotection; SK-N-SH neuroblastoma; cell plating density; serum deprivation; tamoxifen

---

INTRODUCTION

Estrogens have been shown to be important for the differentiation of certain nuclei of the brain (Gorski et al., 1980), and recent evidence suggests that estrogens may be important for normal brain function throughout life (Simpkins et al., 1994). In adult rats, estradiol (E2) has been shown to enhance sprouting of commissural association fibers in the hippocampal dentate gyrus after entorhinal cortex lesions (Morse et al., 1986). Estrogen environment influences the synaptology of the hippocampus, because changes in synaptic density in the CA1 region are associated with endogenous (Wooley and McEwen, 1992) and exogenous (Wooley et al., 1990) levels of 17-estradiol (17-E2). Recently, we have shown that 17-E2 induced the expression of the neurotrophic factors, nerve growth factor, and brain-derived neurotrophic factor (Singh et al., 1993, 1995). We and others have observed an increase in the high affinity uptake of choline (O'Malley et al., 1987; Singh et al., 1994), in the levels of choline acetyltransferase (Luine et al., 1975, 1980; Singh et al., 1994), and in the performance of memory-related behavioral tasks (Singh et al., 1994) after estrogen treatment of ovariectomized rats. Collectively, these results indicate that estrogens are important in the maintenance of normal neuronal function related to cognition, an observation consistent with the studies of Sherwin et al. (Sherwin, 1988; Phillips and Sherwin, 1992) showing steroid modulation of memory and cognition in women subjected to surgical menopause.

Estrogens seem to exert neurotrophic and neuroprotective effects on a variety of cell types. Toran-Allerand (1976) first reported growth stimulation by estrogens of explants of the hypothalamus and preoptic area of the basal diencephalon. More recently, we have observed that estrogens protect transformed neurons and glia from the cytotoxic effects of a variety of insults, including serum deprivation (Bishop and Simpkins, 1994) and hypoglycemia (Bishop et al., 1994). 17-E2 was particularly effective in protecting SK-N-SH neuroblastoma cells from the neurotoxic effects of serum deprivation (Bishop and Simpkins, 1994). This cell line is human in origin, expresses a neuronal phenotype, is estrogen-responsive (Ratka et al., 1991), and expresses estrogen receptors mRNA (Ratka et al., 1995) and the protein and message for nerve growth factor (Azar et al., 1991).

The studies cited above have used the 17-isomer of E2, which is known to interact potently with the estrogen receptor (Korenman, 1969; Lubahn et al., 1985) and the estrogen receptor (ER)-17-E2 complex binds with a longer duration to the estrogen-responsive element (Clark et al., 1982). By contrast 17-E2 binds weakly to the estrogen receptor; the 17-E2-ER complex only transiently binds to the estrogen-responsive element (Korenman, 1969; Clark et al., 1982; Lubahn et al., 1985). When administered acutely, -E2 has only weak (Korenman, 1969) or no (Huggins et al., 1954; Kneifel et al., 1982) activity in peripheral estrogen-responsive tissues but seems to exert uterotropic effects with administration chronically at high doses (Clark et al., 1982; Clark and Markaverich, 1983).

The present study was undertaken to compare the relative activities of the - and -isomers of E2 in a test of the neuroprotective effect of estrogens. Surprisingly, both isomers of E2 were equally effective in protecting SK-N-SH cells from the cytotoxic effects of serum deprivation.

---

MATERIALS AND METHODS

Cell cultures. SK-N-SH cells were obtained from American Type Tissue Collection (Rockville, MD). Cell cultures were grown to confluency in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin G, and 100 µg/ml streptomycin (all reagents from Sigma, St. Louis, MO) in monolayers in plastic Corning 150 cm² flasks (Sigma) at 37°C and under 5% CO₂/95% air. Medium was changed three times weekly. Cells were observed with a phase-contrast microscope (Nikon Diaphot-300).

SK-N-SH cells were back-cultured every 5-7 d to maintain the cell line, and cells used in the following experiments were located in passes 9-12. The growth media were initially decanted, and the cells were rinsed with 6 ml of 0.02% EDTA, which was discarded. Then another 6 ml of 0.02% EDTA was added. After a 30 min incubation at 37°C, the cells were counted on a Neubauer hemacytometer (Fisher Scientific, Orlando, FL) and resuspended in appropriate media. Cells were plated at a density of 1.0 × 10⁶ cells/ml.

Experimental media. Experiments were initiated by the back-culturing of SK-N-SH cells. Cells were suspended and centrifuged at 1000 rpm for 5 min. The cell pellet was resuspended in the appropriate treatment medium at a concentration of 1.0 × 10⁶ cells/ml. Cells were plated either at 0.25 ml/well (low density plating) or 1 ml/well (high density plating) in 24 well Falcon plates (Fisher Scientific). In all studies, cells were cultured in RPMI-1640 media (serum-free, SF group), RPMI-1640 media supplemented with 10% FBS (FBS group), or RPMI-1640 media supplemented with one of the following steroids at the dose(s) indicated: 17-estradiol (17-E2, 0.2 or 2 nM; Pharmos, Alachua, FL); 17-estradiol (17-E2, 0.2 or 2 nM; Sigma); cholesterol (CHOL, 2 nM; Steraloids, Wilton, NH); testosterone (TEST, 2 nM; Steraloids); dihydrotestosterone (DHT, 2 nM; Steraloids); or corticosterone (CORT, 2 nM; Steraloids). In one study, a 10-fold molar excess of tamoxifen (20 nM; Steraloids) was administered at the same time as 17-E₂ (2 nM) or 17-E₂ (2 nM). In another study, tamoxifen (0 to 200 nM) was administered in the presence or absence of 17-E2 (2 nM). All steroids were dissolved initially at 1 mg/ml in absolute ethanol and diluted in RPMI-1640 to a final concentration of 2 nM. To control for possible ethanol effects in the steroid-treated wells, we supplemented both the serum-free media (control group) and FBS media (FBS group) with absolute ethanol at a concentration of 0.0001% (v/v).

Quantitation of cell viability. Cell viability was assessed at 24 and/or 48 hr of treatment using the trypan blue dye exclusion method (Black and Berenbaum, 1964; Tennant, 1964). At the appropriate time, cell suspensions were made by decanting the media, rinsing each well with 0.2 ml of 0.02% EDTA, and then incubating cells with 0.2 ml of 0.02% EDTA at 37°C for 30 min. Cells were suspended by repeated pipetting of the EDTA over the cells. Aliquots (100 µl) from each cell suspension were incubated with 100 µl of 0.4% trypan blue stain (Sigma) for 5 min at room temperature. All suspensions were counted on a Neubauer hemacytometer (Fisher Scientific) within 15 min of the addition of trypan blue. Two independent counts of live cells were made for each aliquot.

Statistical analysis. The significance of differences among groups was determined by one-way ANOVA. Planned comparisons between groups used was done by Scheffe's F-test. For all tests, p < 0.05 was considered significant.

---

RESULTS

Serum deprivation had a marked effect on the viability of SK-N-SH cells at both high and low plating density (Table 1). At high plating density (1 × 10⁶ cells/well) and in the presence of FBS, 52-60% of cells died in the first 24 hr, and then live cell number increased slightly for the next 24 hr. By contrast, serum deprivation at high plating density resulted in a loss of 77-86% plated cells by 24 hr and 83-91% of cells by 48 hr. At low plating density (0.25 × 10⁶ cells/well), the presence of FBS maintained live cell number constant through 48 hr of the studies. Serum deprivation at low plating density reduced live cells by 82% at 24 hr and by 91% at 48 hr. The effects of FBS and serum deprivation on SK-N-SH cells at a high plating density are similar to our previously reported observation using flasks, as opposed to wells, for culturing of this line of neuroblastoma cells (Bishop and Simpkins, 1994).

Table 1. Effects of serum deprivation and 17-estradiol on SK-N-SH cell number after plating at high and low density Treatment Plating density Culture duration (hr) 24 Cells/well (×103) 48 FBS 1000 405  ± 21 452  ± 51 SF 1000 140  ± 11* 87  ± 7* FBS 1000 480  ± 50 530  ± 100 SF 1000 230  ± 20* 130  ± 20* 17-E2 (2 nM) 1000 480  ± 50 300  ± 60 FBS 250 235  ± 12 232  ± 6 SF 250 42  ± 2* 26  ± 2* * p < 0.05 versus FBS group.

We have observed previously a potent cytoprotective effect of 17-E2 on SK-N-SH cultured at high density in SF media (Bishop and Simpkins, 1994). As a control, we tested the presumed weak or inactive optical isomer, 17-E2, in an initial study (Table 1). Surprisingly, as we had reported previously for 17-E2, 17-E2 partially prevented the death of SK-N-SH cells in response to serum deprivation. When compared with the SF group, live cell numbers were 2.1- and 2.3-fold higher in culture grown for 24 and 48 hr, respectively, in the presence of 2 nM 17-E2, indicating a neuroprotective effect of the -isomer.

In a subsequent study, we compared the effectiveness of 17-E2 effect with the naturally occurring 17-E2 (Fig. 1). With initial plating at high density (1 × 10⁶ cells/well), both the - and -isomers caused a dose-dependent increase in live cell number at 48 hr in culture (Fig. 1). For both isomers, SK-N-SH cells were protected by 65% at the 0.2 nM dose and by 88% at the 2 nM dose versus the nonsteroid-treated cells.

---

Fig. 1. Effects of - and -estradiol on live SK-N-SH cell number after plating of cells at high density. Cells were plated at 1 × 10⁶ cells per well, and cell number was determined 48 hr later. All wells were deprived of serum for the entire incubation period. Wells were treated either with no steroid (Control) or with -estradiol or -estradiol at the concentrations indicated. *p < 0.05 versus control; **p < 0.05 versus control and -E2 groups at 2 nM. There were no differences between - and -estradiol groups at the same doses of the steroid. n = 4 wells per group.
[View Larger Version of this Image (18K GIF file)]

---

The time course of the effect of 17-E2 and 17-E2 was evaluated in SK-N-SH cultures plated at a low density (Fig. 2). At 24 hr of treatment (Fig. 2A), the low dose of both E2 isomers was ineffective in preventing the serum deprivation-induced cell loss. However, the 2 nM concentration produced a 54% protection for the -isomer and a 116% protection for the -isomers. At 48 hr of culture, both - and -isomers caused a 86-106% and 172-189% protection of cells at the 0.2 and the 2 nM concentrations, respectively (Fig. 2B).

---

Fig. 2. Effects of - and -estradiol on live SK-N-SH cell number after plating of cells at low density. Cells were plated at 0.25 × 10⁶ cells per well, and cell number was determined at 24 (A) or 48 hr (B) later. All wells were deprived of serum for the entire incubation period. Wells were treated either with no steroid (Control) or with -estradiol or -estradiol at the concentrations indicated. A, *p < 0.05 versus control; **p < 0.05 versus control and both isomers at the 0.2 nM concentration. B, *p < 0.05 versus control and -E2 groups at 2 nM. **p < 0.05 versus all other groups. n = 6 wells per group for both studies.
[View Larger Version of this Image (17K GIF file)]

---

Tamoxifen alone had no effect on live cell number in SF cultures (Fig. 3), even when administered at concentrations ranging from 2 to 200 nM (data not shown). Coadministration of a 10-fold molar excess of tamoxifen with 17-E₂ or 17-E₂ reduced the neuroprotective effect of the estrogen by 39 and 32%, respectively (Fig. 3). The tamoxifen effect on 17-E2 neuroprotection was not evident at 2 nM, was 32% at 20 nM, and was not enhanced further at 200 nM (Fig. 4).

---

Fig. 3. Effects of treatment with tamoxifen (TAM, 20 nM), 17-estradiol (-E₂, 2 nM), 17-estradiol (a-E2, 2 nM), or their combination on live cell number. Cells were plated at 1 × 10⁶ cell per well, and cell number was determined 48 hr later. Cells were deprived of serum during the entire incubation period. *p < 0.05 versus Control (serum-free) and TAM groups. a = p < 0.05 versus the 17-E₂ group. n = 5-6 wells per group.
[View Larger Version of this Image (13K GIF file)]

---

---

Fig. 4. Effects of treatment with 17-estradiol (2 nM) in the presence of tamoxifen (0-200 nM) on live SK-N-SH cell number. Cells were plated initially at 1 × 10⁶ cells/ml, and cell number was determined 48 hr later. Cells were serum-deprived during the entire incubation period. *p < 0.05 versus control (serum-free) cultures. n = 4-5 wells per group.
[View Larger Version of this Image (16K GIF file)]

---

To assess the specificity of this estrogen effect on SK-N-SH cells, we tested in both high and low density cultures a variety of steroids, including cholesterol, progesterone, testosterone, dihydrotestosterone, and corticosterone. At 48 hr of culture, the time of the peak effect of both 17- and 17-E2, none of the substances tested protected cells from the cytotoxic effects of serum deprivation (Table 2).

Table 2. Effects of various steroids and plating density on the live SK-N-SH cell number at 48 hr Low plating density High plating density Treatment Live cell number (×103) Live cell number (×103) Serum-free control 22.4  ± 1.4 94.4  ± 7.3 Cholesterol 18.3  ± 1.1 64.8  ± 3.9 Progesterone 21.3  ± 0.7 57.6  ± 6.2* Testosterone 20.0  ± 4.2 87.2  ± 6.3 Dihydrotestosterone 20.7  ± 2.6 90.0  ± 7.7 Corticosterone 19.7  ± 1.3 68.8  ± 6.9 All cultures were deprived of serum and exposed to the respective steroid (2 nM) during the entire 48 hr incubation period. * p < 0.05 versus control group; n = 5-8 wells per group.

---

DISCUSSION

The present study demonstrates for the first time that 17-E2, a weak estrogen receptor agonist (Huggins et al., 1954; Korenman, 1969; Clark et al., 1982; Kneifel et al., 1982; Clark and Markaverich, 1983; Lubahn et al., 1985), is as effective as 17-E2 in protecting SK-N-SH cells from the cytotoxic effects of serum deprivation. These results suggest that the estrogenic effect on neuroblastoma cell survival is mediated via a mechanism that does not require binding to the cytosolic estrogen receptor. This conclusion is consistent with the observation that the simultaneous addition of a 10-fold molar excess of the estrogen receptor antagonist, tamoxifen, reduced the neuroprotective effects of both estrogens by only one-third, and a 100-fold molar excess of tamoxifen had no additional effect on the 17-E2 response. This effect is not attributable to a general steroid structure, because cholesterol, a progestin, androgens, and a glucocorticoid were ineffective in protecting SK-N-SH cells from the effects of serum deprivation. In fact, concentrations of progesterone and corticosterone as high as 200 nM were ineffective in protecting SK-N-SH cells from the cytotoxic effects of serum deprivation (J. W. Simpkins and P. S. Green, unpublished observations).

Serum deprivation is a well described insult to most neuronal cells in culture (Bishop and Simpkins, 1994). In the present study, we observed that at either low or high plating density, 90% of SK-N-SH cells failed to survive for 2 d in the absence of FBS. In the presence of FBS, plating conditions influenced the initial survival of cells, with higher plating density resulting in a lower percentage of cell survival. Presumably, with high plating density, competition for plating surface area resulted in lower cell survival. The exact mechanism by which serum deprivation kills neuronal cells in culture is not known. It is unlikely that the estrogen content of FBS is a factor. The fetal serum used has an E2 concentration of 0.06 nM (J. W. Simpkins, unpublished data) and is reported to contain estrone (0.1 nM) and estriol (0.04 nM) (Tissue Culture Technical Service, Sigma). With its dilution to 10% with RPMI medium, which contains no estrogens, the total estrogen content in the growth medium is 0.02 nM, which is too low to exert an estrogen effect on these cells in vitro (Simpkins, unpublished observations).

At both low and high density plating, both 17-E2 and 17-E2 protected SK-N-SH cells. The comparatively lower protective effects of the two isomers in the high density cultures is likely attributable to either (1) the fourfold lower steroid-to-cell ratio in the high density cultures or (2) the plating of cultures at near confluence in the high plating density cultures, a condition that results in the loss of cells because of competition for surface area of the plates. Nonetheless, the data indicate that at both high and low plating density, both estradiol isomers are neuroprotective.

We observed that both 17- and 17-E2 exerted effects on SK-N-SH cells at physiologically relevant concentrations. These data indicate that E2 concentrations observed in rodents and in women can serve a neuroprotective effect. In rats, neurotrophic (Toran-Allerand, 1976, 1980; Faivre-Bauman et al., 1981; Nishizuka and Arai, 1981; Toran-Allerand et al., 1983; Morse et al., 1986; Wooley et al., 1990; Wooley and McEwen, 1992) and neuroprotective (Bishop and Simpkins, 1994; Bishop et al., 1994; Singh et al., 1994; Behl et al., 1995; Goodman et al., 1996) effects of 17-E2 have been described. However, to our knowledge, 17-E2 has not been demonstrated previously to exert either neurotrophic or neuroprotective effects.

Because chronic exposure to high doses of 17-E₂ has been reported to exert uterotropic effects in ovariectomized rats attributable to the chronic occupancy of the estrogen receptor with this weak agonist (Clark and Markaverich, 1993), we assessed the antagonism by tamoxifen of the neuroprotective effects of both 17- and 17-E₂. The absence of an effective antagonism by tamoxifen of this response to either isomer indicates that a cytosolic estrogen receptor mechanism is not the primary mechanism of the observed neuroprotection.

We considered the possibility that the observed effects of 17-E2 may have been subsequent to its conversion by 17-oxidoreductase to estrone and subsequent reduction of the 17-ketone to 17-E2 (Breuer and Schott, 1966; Williams and Layne, 1967). However, this is an extremely unlikely possibility in that 17-oxidoreductase activity is low in human tissue (Breuer and Schott, 1966; Williams and Layne, 1967), relative to that seen in other species (Mulay et al., 1968; Ivie et al., 1986). The conversion of 17-E2 to estrone is reported to be <6%, both in vivo and in liver homogenates in vitro (Breuer and Schott, 1966; Williams and Layne, 1967). In our in vitro system, such a low conversion of 17-E2 to estrone would express itself as a markedly lower potency for the -isomer. Our observation of equal effectiveness of the two isomers indicates that metabolic activation of 17-E2 is not involved in its cytoprotective effects.

Nongenomic actions of 17-E2 are now well described. Direct effects of estrogens on neuronal membranes have been shown to involve specific membrane receptors (Pietras and Szego, 1979); 17-E2 has been shown to increase hippocampal slice CA1 field potentials (Teyler et al., 1980) and to potentiate excitatory postsynaptic potentials of CA1 neurons within 2 min of its addition to slices (Wong and Moss, 1991, 1992), a time too short to involve a transcriptional mechanism. Local application of 17-E2 also has been shown to alter Ca²⁺ fluxes in granulosa cells (Morley et al., 1992)and endometrial cells (Nemere and Norman, 1992) and to increase Ca²⁺ currents in GH₃ anterior pituitary cells (Richie, 1993). As such, we presume that both 17- and 17-E2 can exert their neuroprotective effects via a mechanism that does not require an interaction of the steroid with the estrogen receptor and the subsequent activation of genes. Indeed, recent evidence for the antioxidant activity of estradiol in a cell line that lacks the estrogen receptor (Behl et al., 1995) supports this contention.

The potential relevance of the observed neuroprotective effects of estrogen is demonstrated by the retrospective observation of a 40% reduction in the incidence of Alzheimer's disease in women who had used estrogens postmenopausally (Paganini-Hill and Henderson, 1994) and three reports of improvements in symptoms of Alzheimer's disease in some women with estrogen replacement therapy (Fillit et al., 1986; Honjo et al., 1989; Ohkura et al., 1994). The observed neuroprotective effects of the 17-E2 isomer suggest that this compound may be particularly useful in achieving a selective neuroprotective action of estrogens without overstimulation of peripheral estrogen-responsive tissues.

---

FOOTNOTES

Received Sept. 23, 1996; accepted Oct. 23, 1996.

  

This work was supported by National Institutes of Health Grants AG10485 and T32-NS07333. We thank Victoria Redd for typing and editorial review of this manuscript.

Correspondence should be addressed to Dr. James W. Simpkins, College of Pharmacy, Box 100487, University of Florida, Gainesville, FL 32610.

---

REFERENCES

• Azar C, Scavarda NJ, Reynolds CP, Brodeur GM (1991) Multiple defects of the nerve growth factor receptor in human neuroblastomas. Adv Neuroblastoma Res 3:219-226.
• Behl C, Widmann M, Trapp T, Holsboer F (1995) 17-estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 216:473-482 . [ISI][Medline]
• Bishop J, Simpkins JW (1994) Estradiol treatment increases viability of glioma and neuroblastoma cells in vitro. Mol Cell Neurosci 5:303-308 . [ISI][Medline]
• Bishop J, Singh M, Bodor ET, Simpkins JW (1994) Estradiol stimulates glucose uptake and has cytoprotective effects in rat C₆ glioma cells. Soc Neurosci Abstr 20:294.12.
• Black L, Berenbaum MC (1964) Factors affecting the dye exclusion test for cell viability. Exp Cell Res 35:9-13. [ISI][Medline]
• Breuer H, Schott E (1966) Studies of the metabolism of 17-estradiol in man. J Clin Endocrinol Metab 26:533-536 . [ISI][Medline]
• Clark JH, Markaverich BM (1983) The agonist and antagonistic effects of short-acting estrogens: a review. Pharmacol Ther 21:429-453 . [ISI][Medline]
• Clark JH, Williams M, Upchurch S, Eriksson H, Helton E, Markaverich BM (1982) Effects of estradiol-17 on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites, and uterine growth. J Steroid Biochem 16:323-328 . [ISI][Medline]
• Faivre-Bauman A, Rosenbaum E, Puymirat J, Grouselle D, Tixier-Vidal A (1981) Differentiation of fetal mouse hypothalamic cells in serum-free medium. Dev Neurosci 4:118-129 . [ISI][Medline]
• Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J (1986) Observations in a preliminary open trial of estradiol therapy for senile dementia Alzheimer's type. Psychoneuroendocrinology 11:337-345 . [ISI][Medline]
• Goodman Y, Bruce AJ, Cheng B, Mattson MP (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid -peptide toxicity in hippocampal neurons. J Neurochem 66:1836-1844 . [ISI][Medline]
• Gorski RA, Herlan RE, Jacobson CD, Shryne JE, Southane AM (1980) Evidence for the existence of sexually dimorphic nucleus in the preoptic area of the rat. J Comp Neurol 193:529-539 . [ISI][Medline]
• Honjo H, Ogino Y, Naitoh K, Urabe M, Kitawaki J, Yasuda J, Yamamoto T, Ishihara S, Okada H, Yonezawa T, Hayashi K, Nambara T (1989) In vivo effects by estrogen sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 34:521-525 . [ISI][Medline]
• Huggins C, Jensen EV, Cleveland AS (1954) Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med 100:225-243. [Abstract]
• Ivie CW, Christopher RJ, Munger CE, Coppock CE (1986) Fate and residues of [4-¹⁴C] estradiol-17 after intramuscular injection into Holstein steer calves. J Anim Sci 62:681-690.
• Kneifel MA, Leytus SP, Fletcher E, Weber T, Mangel WF, Katzenellenbogen BS (1982) Uterine plasminogen activator activity: modulation by steroid hormones. Endocrinology 111:493-499 . [Abstract]
• Korenman SG (1969) Comparative binding affinities of estrogens and its relation to estrogenic potency. Steroids 13:163-177 . [ISI][Medline]
• Lubahn DB, McCarty Jr KS, McCarty Sr KS (1985) Electrophoretic characterization of purified bovine, porcine, murine, rat, and human uterine estrogen receptors. J Biol Chem 260:2515-2526 . [Abstract/Free Full Text]
• Luine VN, Khylchevskaya R, McEwen BS (1975) Effects of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 86:293-306 . [ISI][Medline]
• Luine V, Park D, Joh T, Reis D, McEwen B (1980) Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradiol administration. Brain Res 191:273-277 . [ISI][Medline]
• Morley P, Whitfield JF, Vanderhyden BC, Tsang BJ, Schwartz J-L (1992) A new, non-genomic estrogen action: the rapid release of intracellular calcium. Endocrinology 131:1305-1312 . [Abstract]
• Morse JK, Scheff SW, DeKosky ST (1986) Gonadal steroids influence axon sprouting in the hippocampal dentate gyrus: a sexually dimorphic response. Exp Neurol 94:649-658 . [ISI][Medline]
• Mulay S, Henneberry GO, Common RH (1968) Conversion of estradiol-17 to estrone by the hen in vivo. Steroids 12:89-99.
• Nemere I, Norman AW (1992) Steroid hormone actions at the plasma membrane: inducted calcium uptake and exocytotic events. Mol Cell Endocrinol 80:C165-C169.
• Nishizuka M, Arai Y (1981) Organizational action of estrogen on synaptic pattern in the amygdala: implications for sexual differentiation of the brain. Brain Res 213:422-426 . [ISI][Medline]
• Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N (1994) Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1:125-130.
• O'Malley CA, Hautamaki RD, Kelley M, Meyer EM (1987) Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, ACh synthesis, and release from rat cerebral cortical synaptosomes. Brain Res 403:389-392. [ISI][Medline]
• Paganini-Hill A, Henderson VW (1994) Estrogen deficiency increases the risk of Alzheimer's disease in women. Am J Epidemiol 140:256-261 . [Abstract/Free Full Text]
• Phillips SM, Sherwin BB (1992) Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17:485-495 . [ISI][Medline]
• Pietras RJ, Szego CM (1979) Metabolism and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding sites for 17-estradiol. J Cell Physiol 98:145-159 . [ISI][Medline]
• Ratka A, Hochhaus G, Wissler RN, Simpkins JW (1991) CAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone. Mol Cell Endocrinol 78:155-162 . [ISI][Medline]
• Ratka A, Mambourg SE, Singh M (1995) Effects of estradiol on luteinizing hormone-releasing hormone in SK-N-SH neuroblastoma cells. Soc Neurosci Abstr 21:1394.
• Richie AK (1993) Estrogen increases low voltage-activated calcium current density in GH3 anterior pituitary cells. Endocrinology 132:1621-1629. [Abstract]
• Sherwin BB (1988) Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 13:345-357 . [ISI][Medline]
• Simpkins JW, Singh M, Bishop J (1994) The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 15:S195-S197 .
• Singh M, Meyer EM, Millard WJ, Simpkins JW (1993) Ovariectomy reduces ChAT activity and NGF mRNA levels in the frontal cortex and hippocampus of the female Sprague Dawley rat. Soc Neurosci Abstr 19:254.
• Singh M, Meyer EM, Millard WJ, Simpkins JW (1994) Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague Dawley rats. Brain Res 644:305-312 . [ISI][Medline]
• Singh M, Meyer EM, Simpkins JW (1995) The effects of ovariectomy and estradiol replacement on brain-derived neurotrophic factor mRNA expression in cortical and hippocampal brain regions of female Sprague Dawley rats. Endocrinology 136:2320-2324 . [Abstract]
• Tennant JR (1964) Evaluations of the trypan blue technique for determination of cell viability. Transplantation 2:685-694.
• Teyler TJ, Vardaris RM, Lewis D, Rawitch AB (1980) Gonadal steroids: effects on the excitability of hippocampal pyramidal cells. Science 209:1017-1019 . [Abstract/Free Full Text]
• Toran-Allerand CD (1976) Sex steroids and the development of the newborn mouse hypothalamus and preoptic area in vitro: implications for sexual differentiation. Brain Res 106:407-412 . [ISI][Medline]
• Toran-Allerand CD (1980) Sex steroids and the development of the newborn mouse hypothalamus and preoptic area in vitro. II. Morphological correlates and hormonal specificity. Brain Res 189:413-427 . [ISI][Medline]
• Toran-Allerand CD, Hashimoto K, Greennough WT, Saltarelli M (1983) Sex steroids and the development of the newborn mouse hypothalamus and preoptic area in vitro. III. Effects of estrogen on dendritic differentiation. Dev Brain Res 7:97-101.
• Williams KIH, Layne DS (1967) Metabolism of 17-estradiol-6,7-³H by nonpregnant women. J Clin Endocrinol Metab 27:159-164. [ISI][Medline]
• Wong M, Moss RL (1991) Electrophysiological evidence for a rapid membrane action of gonadal steroids, 17-estradiol, on CA1 pyramidal neurons of the rat hippocampus. Brain Res 543:148-152 . [ISI][Medline]
• Wong M, Moss RL (1992) Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci 12:3217-3225 . [Abstract]
• Wooley CS, McEwen BS (1992) Estradiol mediates fluctuations in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 12:2549-2554. [Abstract]
• Wooley CS, Gould E, Frankfurt M, McEwen BS (1990) Naturally occurring fluctuations in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci 10:4035-4039. [Abstract]

---

Copyright ©1997 Society for Neuroscience   0270-6474/1997/17511-05$05.00/0

This article has been cited by other articles:

				J. W. Gatson and M. Singh Activation of a Membrane-Associated Androgen Receptor Promotes Cell Death in Primary Cortical Astrocytes Endocrinology, May 1, 2007; 148(5): 2458 - 2464. [Abstract] [Full Text] [PDF]

				M. Yao, T.-V. V. Nguyen, and C. J. Pike Estrogen Regulates Bcl-w and Bim Expression: Role in Protection against {beta}-Amyloid Peptide-Induced Neuronal Death J. Neurosci., February 7, 2007; 27(6): 1422 - 1433. [Abstract] [Full Text] [PDF]

				M. E. Jung, A. M. Wilson, and J. W. Simpkins A Nonfeminizing Estrogen Analog Protects against Ethanol Withdrawal Toxicity in Immortalized Hippocampal Cells J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 543 - 550. [Abstract] [Full Text] [PDF]

				X. Wang, J. A. Dykens, E. Perez, R. Liu, S. Yang, D. F. Covey, and J. W. Simpkins Neuroprotective Effects of 17beta-Estradiol and Nonfeminizing Estrogens against H2O2 Toxicity in Human Neuroblastoma SK-N-SH Cells Mol. Pharmacol., July 1, 2006; 70(1): 395 - 404. [Abstract] [Full Text] [PDF]

				M. Singh, J. A. Dykens, and J. W. Simpkins Novel Mechanisms for Estrogen-Induced Neuroprotection. Experimental Biology and Medicine, May 1, 2006; 231(5): 514 - 521. [Abstract] [Full Text] [PDF]

				K. D. Yi, J. Chung, P. Pang, and J. W. Simpkins Role of Protein Phosphatases in Estrogen-Mediated Neuroprotection J. Neurosci., August 3, 2005; 25(31): 7191 - 7198. [Abstract] [Full Text] [PDF]

				D. A. Schreihofer, K. D. Do, and A. M. Schreihofer High-soy diet decreases infarct size after permanent middle cerebral artery occlusion in female rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2005; 289(1): R103 - R108. [Abstract] [Full Text] [PDF]

				J. A. DYKENS, W. H. MOOS, and N. HOWELL Development of 17{alpha}-Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study Ann. N.Y. Acad. Sci., June 1, 2005; 1052(1): 116 - 135. [Abstract] [Full Text] [PDF]

				J. W. SIMPKINS, Y. WEN, E. PEREZ, S. YANG, and X. WANG Role of Nonfeminizing Estrogens in Brain Protection from Cerebral Ischemia: An Animal Model of Alzheimer's Disease Neuropathology Ann. N.Y. Acad. Sci., June 1, 2005; 1052(1): 233 - 242. [Abstract] [Full Text] [PDF]

				P. S. Green, K. Bales, S. Paul, and G. Bu Estrogen Therapy Fails to Alter Amyloid Deposition in the PDAPP Model of Alzheimer's Disease Endocrinology, June 1, 2005; 146(6): 2774 - 2781. [Abstract] [Full Text] [PDF]

				M. E. Jung, M. B. Gatch, and J. W. Simpkins Estrogen Neuroprotection Against the Neurotoxic Effects of Ethanol Withdrawal: Potential Mechanisms Experimental Biology and Medicine, January 1, 2005; 230(1): 8 - 22. [Abstract] [Full Text] [PDF]

				M. A. Sortino, M. Chisari, S. Merlo, C. Vancheri, M. Caruso, F. Nicoletti, P. L. Canonico, and A. Copani Glia Mediates the Neuroprotective Action of Estradiol on {beta}-Amyloid-Induced Neuronal Death Endocrinology, November 1, 2004; 145(11): 5080 - 5086. [Abstract] [Full Text] [PDF]

				Y. Xia and T. L. Krukoff Estrogen Induces Nitric Oxide Production via Activation of Constitutive Nitric Oxide Synthases in Human Neuroblastoma Cells Endocrinology, October 1, 2004; 145(10): 4550 - 4557. [Abstract] [Full Text] [PDF]

				Y. Zhang, N. Champagne, L. K. Beitel, C. G. Goodyer, M. Trifiro, and A. LeBlanc Estrogen and Androgen Protection of Human Neurons against Intracellular Amyloid {beta}1-42 Toxicity through Heat Shock Protein 70 J. Neurosci., June 9, 2004; 24(23): 5315 - 5321. [Abstract] [Full Text] [PDF]

				S.-H. YANG, R. LIU, S. S. WU, and J. W. SIMPKINS The Use of Estrogens and Related Compounds in the Treatment of Damage from Cerebral Ischemia Ann. N.Y. Acad. Sci., December 1, 2003; 1007(1): 101 - 107. [Abstract] [Full Text] [PDF]

				L. Prokai, K. Prokai-Tatrai, P. Perjesi, A. D. Zharikova, E. J. Perez, R. Liu, and J. W. Simpkins Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection PNAS, September 30, 2003; 100(20): 11741 - 11746. [Abstract] [Full Text] [PDF]

				A. L. Mize, R. A. Shapiro, and D. M. Dorsa Estrogen Receptor-Mediated Neuroprotection from Oxidative Stress Requires Activation of the Mitogen-Activated Protein Kinase Pathway Endocrinology, January 1, 2003; 144(1): 306 - 312. [Abstract] [Full Text] [PDF]

				C. D. Toran-Allerand, X. Guan, N. J. MacLusky, T. L. Horvath, S. Diano, M. Singh, E. S. Connolly Jr, I. S. Nethrapalli, and A. A. Tinnikov ER-X: A Novel, Plasma Membrane-Associated, Putative Estrogen Receptor That Is Regulated during Development and after Ischemic Brain Injury J. Neurosci., October 1, 2002; 22(19): 8391 - 8401. [Abstract] [Full Text] [PDF]

				R. Liu, S.-H. Yang, E. Perez, K. D. Yi, S. S. Wu, K. Eberst, L. Prokai, K. Prokai-Tatrai, Z. Y. Cai, D. F. Covey, et al. Neuroprotective Effects of a Novel Non-Receptor-Binding Estrogen Analogue: In Vitro and In Vivo Analysis Stroke, October 1, 2002; 33(10): 2485 - 2491. [Abstract] [Full Text] [PDF]

				Y.-H. Suh and F. Checler Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525. [Abstract] [Full Text] [PDF]

				D. E. DLUZEN and J. L. McDERMOTT Estrogen, Anti-Estrogen, and Gender: Differences in Methamphetamine Neurotoxicity Ann. N.Y. Acad. Sci., June 1, 2002; 965(1): 136 - 156. [Abstract] [Full Text] [PDF]